Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125I-14,15-epoxyeicosa-8(Z)- enoic acid

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 3, 2008, Pages 1019-1027

  Yang, Wenqi ^a   Tuniki, Venugopal Raju ^b   Anjaiah, Siddam ^b   Falck, J R ^b   Hillard, Cecilia J ^a   Campbell, William B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 14,15 DIHYDROXYEICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 14,15 EPOXYEICOSA 5 ENOIC ACID; 14,15 EPOXYEICOSATRIENOIC ACID THIIRANE; 15 HYDROXYICOSATETRAENOIC ACID; 20 IODO 14,15 EPOXYEICOSA 8 ENOIC ACID I 125; CYCLIC AMP; EPOXYICOSATRIENOIC ACID; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); ICOSANOID; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL MEMBRANE; CELL STRAIN U937; CONTROLLED STUDY; CORONARY ARTERY; COW; DRUG ACTIVITY; DRUG BINDING; DRUG COMPETITION; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ARACHIDONIC ACIDS; BINDING SITES; CATTLE; CELL MEMBRANE; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IODINE RADIOISOTOPES; U937 CELLS;

EID: 40849139451     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.129577     Document Type: Article

References (41)

1. Barrington WW, Jacobson KA, Hutchison AJ, Williams M, and Stiles GL (1989) Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc Natl Acad Sci U S A 86:6572-6576.
2. Cai G, Zhu W, and Ma D (2006) A sequential reaction process to assemble polysubstituted indolizidines, quinolizidines and quinolizidine analogs. Tetrahedron 62:5697-5708.
3. Campbell WB and Falck JR (2007) Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension 49:590-596.
4. Campbell WB, Gebremedhin D, Pratt PF, and Harder DR (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78:415-423.
5. Carroll MA, Doumad AB, Li J, Cheng MK, Falck JR, and McGiff JC (2006) Adenosine A2 receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway. Am J Physiol Renal Physiol 291:F155-F161.
6. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. Corey EJ, Niwa H, and Falck JR (1979) Selective epoxidation of eicosa-cis-5,8,11,14-tetraenoic (arachidonic) acid and eicosa-cis-8,11,14- trienoic acid. J Am Chem Soc 101:1586-1587.
8. Cunha RA, Constantino MD, and Ribeiro JA (1999) G protein coupling of CGS 21680 binding sites in the rat hippocampus and cortex is different from that of adenosine A1 and striatal A2A receptors. Naunyn Schmiedebergs Arch Pharmacol 359:295-302.
9. Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, and Endres S (1998) Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol 63:101-107.
10. Falck JR, Krishna UM, Reddy YK, Kumar PS, Reddy KM, Hittner SB, Deeter C, Sharma KK, Gauthier KM, and Campbell WB (2003a) Comparison of vasodilatory properties of 14,15-EET analogs: structural requirements for dilation. Am J Physiol Heart Circ Physiol 284:H337-H349.
11. Falck JR, Reddy LM, Reddy YK, Bondlela M, Krishna UM, Ji Y, Sun J, and Liao JK (2003b) 11,12-epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-alpha-induced VCAM-1 expression. Bioorg Med Chem Lett 13:4011-4014.
12. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R (1999) Cytochrome P450 2C is an EDHF synthase. Nature 401:493-497.
13. Fisslthaler B, Popp R, Michaelis UR, Kiss L, Fleming I, and Busse R (2001) Cyclic stretch enhances the expression and activity of coronary endothelium-derived hyperpolarizing factor synthase. Hypertension 38:1427-1432.
14. Gando S, Hattori Y, Akaishi Y, Nishihira J, and Kanno M (1997) Impaired contractile response to β adrenoceptor stimulation in diabetic rat hearts: alterations in β adrenoceptors-G protein-adenylate cyclase system and phospholamban phosphorylation. J Pharmacol Exp Ther 282:475-484.
15. Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, and Campbell WB (2002) 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res 90:1028-1036.
16. Hide I, Padgett WL, Jacobson KA, and Daly JW (1992) A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase. Mol Pharmacol 41:352-359.
17. Huang A, Sun D, Jacobson A, Carroll MA, Falck JR, and Kaley G (2005) Epoxyeicosatrienoic acids are released to mediate shear stress-dependent hyperpolarization of arteriolar smooth muscle. Circ Res 96:376-383.
18. Karara A, Wei S, Spady D, Swift L, Capdevila JH, and Falck JR (1992) Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma. Biochem Biophys Res Commun 182:1320-1325.
19. King LM, Gainer JV, David GL, Dai D, Goldstein JA, Brown NJ, and Zeldin DC (2005) Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics 15:7-13.
20. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, and Narumiya S (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 122:217-224.
21. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, and Zeldin DC (2006) Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 15:1640-1649.
22. Levinson SL (1984) Peptidoleukotriene binding in guinea pig uterine membrane preparations. Prostaglandins 28:229-240.
23. Li PL and Campbell WB (1997) Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res 80:877-884.
24. Liu PY, Li YH, Chao TH, Wu HL, Lin LJ, Tsai LM, and Chen JH (2007) Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis 195:199-206.
25. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, et al. (2005) The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A 102:16747-16752.
26. iα. J Pharmacol Exp Ther 304:370-379.
27. 2+ ion. Biochim Biophys Acta 1220:76-84.
28. Morin D, Sapena R, Zini R, Onteniente B, and Tillement JP (1997) Characterization of beta-adrenergic receptors of freshly isolated astrocytes and neurons from rat brain. Life Sci 60:315-324.
29. Mosset P, Gree R, and Falck J (1989) Synthesis of two intermediate phosphonium salts for 5,20- and 15,20-diHETES. Synth Commun 19:645-658.
30. Nanoff C, Jacobson KA, and Stiles GL (1991) The A2 adenosine receptor: guanine nucleotide modulation of agonist binding is enhanced by proteolysis. Mol Pharmacol 39:130-135.
31. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, and Liao JK (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285:1276-1279.
32. s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem 276:15983-15989.
33. Pimpinelli F, Rovati GE, Capra V, Piva F, Martini L, and Maggi R (1999) Expression of prostacyclin receptors in luteinizing hormone-releasing hormone immortalized neurons: role in the control of hormone secretion. Endocrinology 140:171-177.
34. Prestwich GD, Eng WS, Robles S, Vogt RG, Wisniewski JR, and Wawrzenczyk C (1988) Synthesis and binding affinity of an iodinated juvenile hormone. J Biol Chem 263:1398-1404.
35. Scornik FS, Codina J, Birnbaumer L, and Toro L (1993) Modulation of coronary smooth muscle KCa channels by Gs alpha independent of phosphorylation by protein kinase A. Am J Physiol Heart Circ Physiol 265:H1460- H1465.
36. Sharif NA and Davis TL (2002) Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol 54:539-547.
37. Snyder GD, Krishna UM, Falck JR, and Spector AA (2002) Evidence for a membrane site of action for 14,15-EET on expression of aromatase in vascular smooth muscle. Am J Physiol Heart Circ Physiol 283:H1936-H1942.
38. Spector AA and Norris AW (2007) Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 292:C996-C1012.
39. Wong PY, Lai PS, and Falck JR (2000) Mechanism and signal transduction of 14 (R), 15 (S)-epoxyeicosatrienoic acid (14,15-EET) binding in guinea pig monocytes. Prostaglandins Other Lipid Mediat 62:321-333.
40. Wong PY, Lai PS, Shen SY, Belosludtsev YY, and Falck JR (1997) Post-receptor signal transduction and regulation of 14(R),15(S)- epoxyeicosatrienoic acid (14,15-EET) binding in U-937 cells. J Lipid Mediat Cell Signal 16:155-169.
41. Wong PY, Lin KT, Yan YT, Ahern D, Iles J, Shen SY, Bhatt RK, and Falck JR (1993) 14(R),15(S)-epoxyeicosatrienoic acid (14(R),15(S)-EET) receptor in guinea pig mononuclear cell membranes. J Lipid Mediat 6:199-208.